Enzo Challenges Bioequivalence Standard
By Ben James ( December 19, 2006, 12:00 AM EST) -- Enzo Pharmaceutical Holdings Inc. has urged U.S. regulators not to rely on a newly proposed standard for determining whether proposed generic substitutes for Endo's Lidoderm topical pain patch meet the requirements for bioequivalence with the brand-name Lidoderm treatment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.